Safety Committee Approves Expansion of Ph I/II DFI Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. announced that an Independent Safety Committee has approved the expansion of its Phase I/II clinical trial for a treatment of diabetic foot infections, confirming the trial is safe and effective. The trial is achieving its primary endpoints of safety, tolerability, and efficacy, with plans to launch additional clinical sites in Australia and internationally.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- RCE Establishes Strategic Partnership in South-East Asia
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
- Murdoch Children's R327 Efficacy UTI in-vivo
- RCE Awarded Further $11.17m Advanced Overseas Finding
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
Later from Recce Pharmaceuticals
- Recce Receives AUD $11.17m R&D Advance
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Patent Granted in Israel for RECCE Anti-Infectives
- Recce Pharmaceuticals - Business Update
- Recce Completes 5,000 R327 Doses Per Week under GMP
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals